Sobi Swedish Orphan Biovitrum Ab Publ
About Company
Sobi is a global biopharma company unlocking the potential of breakthrough innovations, transforming everyday life for people living with rare diseases.
We are dedicated to capturing the scientific opportunities of our time. With our early roots in Sweden, we started as pioneers in haemophilia. Today we are an innovative leader within rare diseases with a global reach. Together we are bringing brilliant ideas to life.
Sobi has approximately 1,900 employees across Europe, North America, the Middle East, Asia and Australia. In 2024, revenue amounted to SEK 26 billion. Sobi’s share (STO:SOBI) is listed on Nasdaq Stockholm. More about Sobi at sobi.com and LinkedIn.
Business Industry
Orphan Drugs, Hereditary Metabolic Disorders, Haemophilia, Biopharmaceuticals, Patient Access, Rare Diseases, Haematology, Hematology, Immunology, Autoimmune
